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Abstract
Background: Late pulmonary metastasis from urothelial carcinoma (UC) of the upper urinary tract is extremely rare.
Case presentation: A 76-year-old man was referred to our hospital due to an abnormal shadow on chest X-ray.
He had a history of left nephrectomy with a diagnosis of UC in the renal pelvis 29 years previously. Computed
tomography showed a mass lesion in the right middle lobe of the lung that measured 4.9 cm in diameter. A
transbronchial biopsy revealed the tumor to be metastatic pulmonary UC, and he underwent right middle
lobectomy of the lung.
Conclusion: Long-term postoperative follow-up of patients with UC might be necessary after radical nephrectomy.
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Background
Urothelial carcinoma (UC) of the upper urinary tract is
uncommon and accounts for only 5 to 10% of UCs, in
contrast with bladder tumors [1]. Some recurrent cases
after long-term latency associated with bladder UC have
been reported; however, there have been very few cases
of late pulmonary metastasis of upper urinary tract UC.
We herein report an extremely rare case of pulmonary
metastasis from the upper urinary tract UC 29 years
after nephrectomy.
Case presentation
A 76-year-old man who had undergone coronary arterial
bypass grafting for ischemic heart disease 3 years previ-
ously was referred to our hospital due to an abnormal
shadow of the right lung detected on chest X-ray during
his usual medical checkup that had not been detected
3 years previously (Fig. 1a). Chest computed tomography
(CT) showed a mass lesion with smooth margin in the
right middle lobe of the lung that measured 4.9 cm in
diameter (Fig. 1b). He also had a history of left
nephrectomy with a diagnosis of UC in the renal pelvis
(pT2N0M0 pStage II) 29 years previously. 18F-
fluorodeoxyglucose-positron emission tomography
(FDG-PET) showed a lung mass with a maximal stan-
dardized uptake value of 10.2 without any other uptake
lesions (Fig. 1c). A transbronchial biopsy of the mass
demonstrated histologic features resembling the past
renal pelvic carcinoma. The mass was strongly suspected
to be a pulmonary metastasis of UC, so he underwent
right middle lobectomy of the lung with hilar lymph
node dissection (Fig. 2a,b). A pathologic examination of
the resected specimen revealed solid nests of tumor cells
with clear cytoplasm including finely granular nuclear
chromatin and inconspicuous nuclei, findings that were
highly consistent with the histology of UC (Fig. 2c).
Immunohistochemically, the specimen was positive for
GATA-binding protein 3 (GATA3) (Fig. 2d) and negative
for thyroid transcription factor-1 (TTF-1). Based on
these findings, the tumor was diagnosed as a pulmonary
recurrence of the previously resected upper urinary tract
UC. The postoperative course was uneventful, and he
was alive without disease 5 months after pulmonary
resection.
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Conclusions
Upper urinary tract UC is a relatively uncommon dis-
ease, accounting for only 5 to 10% of urothelial malig-
nancies. These upper urinary tract cancers are thought
to seed tumor cells to the urinary tract, as concurrent
bladder cancer is present in 8 to 13% of upper urinary
tract UC cases, and recurrence occurs by seeding to
urinary bladder in 30 to 51% of the patients [1]. Hall
et al. reported that the site of the first relapse of resected
upper urinary tract UC was local in the retroperitoneum
(tumor bed, soft tissue, or lymph nodes) (9.0%), in the
bladder (50.8%), in the remaining upper tract (17.9%), or
distantly in the lung, bone, or liver (22.4%) [2]. They also
found that the median time to recurrence after curative
treatment was 12 months (mean, 23.6 months; range, 1–
99 months), and primary tumor stage or surgical proced-
ure performed were important predictors of disease recur-
rence [2]. Although our patient underwent radical
nephrectomy, he had recurrence in the bladder only 1 year
after the operation and was treated with bacilli Calmette
Guerin therapy and transurethral resection. To our know-
ledge, only one case of late pulmonary metastases from
upper urinary tract UC has been reported. In that case, a
pulmonary metastasis with mediastinal lymph adenopathy
and brain metastases developed 12 years after radical
nephrectomy [3].
Metastatic diseases occasionally occur decades after
successful treatment of the primary tumor. It has been
Fig. 1 Radiological findings. a Chest X-ray shows an abnormal shadow of the right lung. b Chest CT shows a mass lesion with a smooth margin
in the right middle lobe of the lung. c FDG-PET shows that the maximal standardized uptake value is 10.2 in the tumor
Fig. 2 Surgical and pathologic findings. a, b Macroscopic findings of the surgical specimen are shown. c The resected specimen of the lung
resembles the previous upper urinary tract urothelial carcinoma. d Immunohistochemically, the tumor was positive for GATA3 in cancer
cells (×200)
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proposed that this latency period is due to a clinical
phenomenon named tumor dormancy. Several re-
searchers have advocated that the dormancy of such
cells might be caused by a non-proliferating state or an
arrest in the cell cycle which thus results in a prolonged
G0 phase [4]. However, these mechanisms including
how these cells can then trigger proliferation have not
yet been fully explored.
GATA3 is useful for differentiating metastatic UC
from other primary or secondary epithelial neoplasms,
including adenocarcinoma and squamous cell carcin-
oma, as well as sarcoma and melanoma. Morphologic-
ally, at least 25% of cases of UC demonstrate foci of
squamous or glandular differentiation and overlap with
adenocarcinoma, such as intracytoplasmic mucin. In the
present case, the tumor was first suspected to be pri-
mary lung cancer on CT, without any consideration of
pulmonary metastasis of UC. GATA3 is a transcription
factor for T cell development and a regulator of estrogen
receptor in breast carcinoma. Immunohistochemical
staining of GATA3 is now used for the diagnostic sup-
port of breast cancer and UC as a tumor marker. Laura
et al. reported that GATA3 expression was positive in
88% of invasive upper urinary tract UC and in 80% of
pulmonary metastases of UC but was negative in pri-
mary pulmonary squamous cell carcinoma [5].
According to the recent guidelines, systemic chemo-
therapy is the standard treatment for patients with meta-
static UC [1]. However, despite initially promising
response rates of up to 70%, most patients will eventu-
ally experience tumor progression. The median survival
following contemporary chemotherapy regimens remains
13–14 months [6]. However, as for the role of surgery in
the management of metastatic UC, Matsuguma et al.
reviewed 32 patients who underwent pulmonary metas-
tasectomy with curative intent. They reported that the
5-year survival after metastasectomy was 50%, and me-
tastasis exceeding 3 cm in size was proven to be a sig-
nificant poor prognostic factor on a multivariate analysis
[7]. Woo et al. reviewed data from 16 patients who
underwent pulmonary metastasectomy with adjuvant
chemotherapy and showed that the 5-year overall and
disease-free survivals were 65.3 and 37.5%, respectively
[8]. They demonstrated a favorable survival rate after re-
peated pulmonary metastasectomy in five patients, two
of whom underwent three resection operations for re-
current disease. Long-term cancer control can be
achieved in a subgroup of patients following surgical re-
moval of metastatic UC, but metastasectomy in patients
with disseminated metastatic UC remains controversial.
Although late pulmonary metastasis of upper urinary
tract UC is extremely rare, physicians should be aware
of occurrence and follow up such patients for a long-
term period as curative re-treatment may be possible.
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